



PRESS RELEASE

GlycoVaxyn AG Appoints Renowned Vaccinologist Dr Stanley Plotkin to Supervisory Board

Schlieren, Switzerland, 6th October, 2009 – GlycoVaxyn, a pioneer in the development of innovative conjugated vaccines, announced today that the world renowned vaccinologist Dr Stanley A Plotkin has been elected to its Supervisory Board.

Among his achievements, Dr Plotkin developed a vaccine against the rubella virus. This rubella vaccine continues to be in standard use throughout the world today. He is also co-developer of a vaccine against rotavirus and has worked extensively on the development and application of other vaccines, including polio, rabies, varicella, rotavirus and cytomegalovirus.

"We are proud and honored that Dr Plotkin has agreed to join the GlycoVaxyn Supervisory Board. His extensive and successful career in developing novel vaccines will be invaluable as we move our vaccines towards clinical evaluation," noted Michel Greco, Chairman of GlycoVaxyn.

"In the vaccine field, GlycoVaxyn stands out because of its unique approach to the development and production of glycoconjugate vaccines," said Dr Plotkin. "This approach could change the way that current vaccines are manufactured and also offers a method to develop vaccines to some of the bacterial targets for which vaccines are non-existent or difficult to produce, such as Shigella, Staphylococcus aureus and Pseudomonas."

Dr Plotkin is Emeritus Professor of the University of Pennsylvania and consultant to many vaccine manufacturers. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania and Professor of Virology at the Wistar Institute, whilst simultaneously being Director of Infectious Diseases and Senior Physician at the Children's Hospital of Philadelphia. In 1991, Dr Plotkin joined the vaccine manufacturer, Pasteur-Mérieux-Connaught (now Sanofi Pasteur), where for seven years he was Medical and Scientific Director.

At various times in his distinguished career, Dr Plotkin's has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health.

Dr Plotkin has received numerous awards, including the Bruce Medal in Preventive Medicine from the American College of Physicians, the Distinguished Physician Award from the Pediatric Infectious Diseases Society, the Clinical Virology Award from the Pan American Society for Clinical Virology, and the Marshall Award from the European Society for Pediatric Infectious Diseases. In June 1998, he received the French Legion of Honor Medal, in June 2001 the Distinguished Alumnus Award of the Children's Hospital of Philadelphia, the Sabin Gold Medal in May 2002 and in September 2004 the Fleming (Bristol) Award from the Infectious Diseases Society of America and in 2009, the Finland Award of the National Foundation for Infectious Diseases and the Hilleman Award of the American Society for Microbiology. He was elected to the Institute of Medicine of the National Academy of Sciences in 2005. Dr Plotkin holds honorary degrees from the University of Pennsylvania and the University of Rouen (France), and the Universidad Complutense of Madrid.

About Conjugated Vaccines

Conjugated vaccines provide protection against a growing range of life-threatening bacterial infections. GlycoVaxyn has developed a proprietary technology that allows the engineering of a new type of conjugate vaccine, glycoconjugates. This innovation will enable GlycoVaxyn to address significant unmet medical needs in both industrialized and emerging countries.

About GlycoVaxyn

GlycoVaxyn has built a broad portfolio of novel conjugate vaccines against common severe bacterial infections based on its unique, proprietary in-vivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a simplified biological process that circumvents many of the difficulties involved in current methods. The lead conjugate vaccines in development are directed against *Shigella dysenteriae*, to prevent serious intestinal infections, and against hospital acquired *Staphylococcus aureus*. GlycoVaxyn also has active programs against *N. meningitidis* and Group A *Streptococcus*. GlycoVaxyn, a spin-out of the Swiss Federal Institute of Technology (ETH), is based in Schlieren, near Zurich, Switzerland. For further information, visit www.glycovaxyn.com.

Contacts:

Philippe Dro
GlycoVaxyn AG
Tel: +41 44 733 8581
philippe.dro@glycovaxyn.com

Mike Sinclair
Halsin Partners
Tel: +44 20 7084 5955
msinclair@halsin.com